Novel Drug Induces Robust Responses in von-Hippel Lindau Disease-Associated Kidney Cancer
At a median follow-up of almost two years, 88.5% of patients remained on study treatment.
Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.
Avoiding the Chemo Chair
Some women with hormone-driven early breast cancer can skip chemotherapy after surgery.
Immunotherapy Combination Improves Melanoma Outcomes, But at a Cost
Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) improved response rates in patients with melanoma, but not without some severe side effects.